Hengrui Pharmaceutical announced that its subsidiaries, Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for injectable SHR-A2009 and adbelimab injections from the State Drug Administration, agreeing to use SHR-A2009 in combination with adbelimab or third-generation EGFR TKI to conduct phase II clinical trials in patients with non-small cell lung cancer. Clinical trials will be carried out in the near future. The total R&D investment for SHR-A2009 related projects for injection is about 329 million yuan, and the total R&D investment for adbelimab injection-related projects is about 1,252 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.